Last updated: April 29, 2026
What is CN121177273 and what does it claim?
CN121177273 is a China patent publication (CN) assigned to a drug-related invention. The patent’s scope and enforceable claim boundaries are determined by the independent claims and their dependent claim sets, as well as by any claim language that ties the invention to a specific compound, polymorph, formulation, dosage, target, route of administration, process, or use.
However, no claim text, bibliographic data (assignee, priority dates, application/publication dates), legal status, or CPC/IPC classification details are provided in the prompt. Without the actual published claims (or at least the claim set headings and wording), a complete and accurate analysis of:
- the independent claim scope,
- the claim element-by-element limitations,
- the likely interpretation of key terms under Chinese practice,
- and the mapping to competitors and family members
cannot be produced.
Which claim types typically define enforceability in China drug patents?
In China drug patents, enforceability usually turns on whether claims are framed as:
- Compound claims (structure-defined active ingredients),
- Composition/formulation claims (drug product definitions, excipient ratios, particle size, polymorph),
- Method-of-treatment claims (medical use tied to a therapeutic indication),
- Method/process claims (manufacture route, intermediates),
- Selection claims (specific members from a broader genus),
- Salt/polymorph/solvate claims (physicochemical form boundaries),
- or Use claims that are dependent on a specific dosage or patient population.
A valid “scope and claims” report requires verbatim claim elements, because scope in China is generally interpreted through the claim wording and the description-supported meaning of terms. Without the claim set, any attempt to describe scope would be non-factual.
What does a CN drug patent landscape analysis require?
A credible patent landscape for a single publication normally requires the following artifacts:
- Bibliographic data: application number, publication number, priority date(s), applicant/assignee, inventors.
- Legal status: active, withdrawn, lapsed, invalidated, or re-examined.
- Family structure: related CN continuations/divisionals, PCT members, EP/US counterparts, and any later amendments.
- Claim mapping: which compounds/uses/formulations are covered by which independent claims.
- CPC/IPC and key technical keywords: for retrieving relevant competitor filings.
- Forward citations and prosecution history (where available): used to identify novelty-limiting prior art and key differentiators.
None of these are available in the prompt.
How does the Chinese landscape usually look around a specific CN publication?
For a drug CN publication, the landscape usually splits into three competing claim “zones”:
- Core compound/form families: competitors file for alternate salts, polymorphs, solvates, and stereochemical forms that sit around structure-based coverage.
- Formulation and manufacturing: covering stability, particle size, capsule/tablet composition, cryoprotectants, lyophilized cakes, or specific process steps.
- Medical use and regimen: indication claims, combination regimens, dosage schedules, and patient subpopulations.
A proper landscape assessment requires the actual CN121177273 claim coverage to determine which zone(s) it occupies and which zones competitors attack.
What claim elements determine infringement risk in China?
In practical China enforcement, infringement risk depends on whether a product or process:
- falls within structural genus/specific embodiment boundaries (for compound claims),
- satisfies composition constraints (for formulation claims),
- matches indication and regimen wording (for medical use claims),
- uses a process step sequence and intermediate set (for method/process claims),
- and avoids explicit exclusions (negative limitations).
These determinations require the actual CN121177273 claim wording.
Patent landscape: competitor and family mapping
A full landscape would normally provide:
- closest prior art categories (CPC/IPC neighbors),
- nearest “same target/same class” filings,
- overlapping families in CN,
- and the likely “freedom to operate” pinch points by claim type.
Because the prompt does not provide:
- claim text,
- CPC/IPC codes,
- assignee/family members,
- or any competitor identifiers,
a landscape cannot be generated without inventing facts, which is not permitted.
What can be concluded from the available prompt?
Nothing about scope, exact claim boundaries, litigation/enforcement prospects, or competitive patent overlap can be stated for CN121177273 based solely on the identifier “CN121177273”.
Key Takeaways
- A scope and claims analysis for CN121177273 requires the published claim set and bibliographic/legal data. None is provided.
- A China-specific patent landscape requires claim mapping and family/classification data. None is provided.
- No factual, actionable assessment of enforceable boundaries or competitor overlap can be completed from the given input.
FAQs
-
Can you determine the enforceable scope of CN121177273 without the claim text?
No. Enforceable scope in China is claim-language driven.
-
Do you need bibliographic data to map families and competitors for CN121177273?
Yes. Landscape work depends on priority, assignee, and related filings.
-
What claim categories most often block generic entry in China?
Compound/form, polymorph/salt, formulation, and medical-use/regimen claims.
-
How is a China drug patent landscape typically structured?
By claim type coverage zones and by overlapping families within CN.
-
What is the minimum dataset needed for a reliable CN drug landscape?
Publication/priority data, legal status, CPC/IPC, and the full claim set.
References
[1] China National Intellectual Property Administration (CNIPA). CN patent publication data (CN121177273).
